Tags

Type your tag names separated by a space and hit enter

Metabolic syndrome and risk of pulmonary involvement.

Abstract

Metabolic syndrome (MS) is a complex disorder recognized clinically by the findings of abdominal obesity, elevated triglycerides, atherogenic dyslipidaemia, elevated blood pressure, high blood glucose and/or insulin resistance. It is associated with a pro-thrombotic and a pro-inflammatory state. A growing body of evidence suggests that individuals in the community with moderate airflow limitation may have co-existing systemic inflammation with this background. Therefore, we examined a population of 237 patients with metabolic disorder for the concomitant presence of functional pulmonary involvement, as assessed by FEV(1) and FVC impairment. Criteria for the identification of the MS included 3 or more of the following: waist circumference: (>102 cm in men, >88 cm in women), triglycerides levels (> or =150 mg/dl), high-density lipoprotein cholesterol levels (<40 mg/dl in men, <50 mg/dl in women), blood pressure (> or =135/> or =85 mmHg), and fasting glucose levels (>100 mg/dl). 119 subjects were diagnosed MS. Non-smokers patients suffering from MS presented lower spirometric values, with a trend to ventilatory restrictive more than obstructive pattern. Also in smokers patients with MS there was a trend to harmonic decrease in FEV(1) and FVC but not in FEV(1)/FVC ratio, although the changes did not reach statistical significance. Mainly abdominal circumference, and also insulin resistance were retained as independent predictors of both FEV(1) and FVC changes. However, HDL-C was the strongest predictor of FEV(1) and FVC changes, with an inverse association.

Links

  • FREE Publisher Full Text
  • Authors+Show Affiliations

    ,

    Department of Internal Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy.

    , , , , , ,

    Source

    Respiratory medicine 104:1 2010 Jan pg 47-51

    MeSH

    Cholesterol, HDL
    Diabetes Mellitus, Type 2
    Female
    Forced Expiratory Volume
    Humans
    Male
    Metabolic Syndrome
    Middle Aged
    Prognosis
    Risk Factors
    Spirometry

    Pub Type(s)

    Journal Article

    Language

    eng

    PubMed ID

    19800211

    Citation

    Rogliani, Paola, et al. "Metabolic Syndrome and Risk of Pulmonary Involvement." Respiratory Medicine, vol. 104, no. 1, 2010, pp. 47-51.
    Rogliani P, Curradi G, Mura M, et al. Metabolic syndrome and risk of pulmonary involvement. Respir Med. 2010;104(1):47-51.
    Rogliani, P., Curradi, G., Mura, M., Lauro, D., Federici, M., Galli, A., ... Cazzola, M. (2010). Metabolic syndrome and risk of pulmonary involvement. Respiratory Medicine, 104(1), pp. 47-51. doi:10.1016/j.rmed.2009.08.009.
    Rogliani P, et al. Metabolic Syndrome and Risk of Pulmonary Involvement. Respir Med. 2010;104(1):47-51. PubMed PMID: 19800211.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Metabolic syndrome and risk of pulmonary involvement. AU - Rogliani,Paola, AU - Curradi,Giacomo, AU - Mura,Marco, AU - Lauro,Davide, AU - Federici,Massimo, AU - Galli,Angelica, AU - Saltini,Cesare, AU - Cazzola,Mario, Y1 - 2009/10/01/ PY - 2009/04/21/received PY - 2009/08/05/revised PY - 2009/08/22/accepted PY - 2009/10/6/entrez PY - 2009/10/6/pubmed PY - 2010/9/10/medline SP - 47 EP - 51 JF - Respiratory medicine JO - Respir Med VL - 104 IS - 1 N2 - Metabolic syndrome (MS) is a complex disorder recognized clinically by the findings of abdominal obesity, elevated triglycerides, atherogenic dyslipidaemia, elevated blood pressure, high blood glucose and/or insulin resistance. It is associated with a pro-thrombotic and a pro-inflammatory state. A growing body of evidence suggests that individuals in the community with moderate airflow limitation may have co-existing systemic inflammation with this background. Therefore, we examined a population of 237 patients with metabolic disorder for the concomitant presence of functional pulmonary involvement, as assessed by FEV(1) and FVC impairment. Criteria for the identification of the MS included 3 or more of the following: waist circumference: (>102 cm in men, >88 cm in women), triglycerides levels (> or =150 mg/dl), high-density lipoprotein cholesterol levels (<40 mg/dl in men, <50 mg/dl in women), blood pressure (> or =135/> or =85 mmHg), and fasting glucose levels (>100 mg/dl). 119 subjects were diagnosed MS. Non-smokers patients suffering from MS presented lower spirometric values, with a trend to ventilatory restrictive more than obstructive pattern. Also in smokers patients with MS there was a trend to harmonic decrease in FEV(1) and FVC but not in FEV(1)/FVC ratio, although the changes did not reach statistical significance. Mainly abdominal circumference, and also insulin resistance were retained as independent predictors of both FEV(1) and FVC changes. However, HDL-C was the strongest predictor of FEV(1) and FVC changes, with an inverse association. SN - 1532-3064 UR - https://www.unboundmedicine.com/medline/citation/19800211/Metabolic_syndrome_and_risk_of_pulmonary_involvement_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0954-6111(09)00278-9 DB - PRIME DP - Unbound Medicine ER -